Adcetris Injection, Powder, Lyophilized, For Solution
Product Images NDC 51144-050

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Adcetris (NDC 51144-050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Seagen Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cartonlabel

Carton label for ADCETRIS (brentuximab vedotin) 50 mg/vial injection, powder, lyophilized, for intravenous use. The label states it is a single-dose vial with reconstitution and dilution required, manufactured by Seagen Inc. Storage instructions specify 2°C to 8°C, protected from light. Includes NDC 51144-050-01 and Rx Only status.*

FDA Label Image

Carton Label (Label)

Label for ADCETRIS injection, powder, lyophilized for solution containing 50 mg/vial of brentuximab vedotin. The label states it is a single-dose vial requiring reconstitution and dilution, intended for intravenous use only. Manufactured by Seagen Inc., Bothell, WA. Includes storage instructions and U.S. license number 2257.*

FDA Label Image

Figure 1 (Figure1)

Kaplan-Meier curve depicting IRF-assessed modified progression-free survival over time in months from randomization for Study 5: ECHELON-1. The graph compares two treatment groups, ADCETRIS plus AVD and ABVD, with probability of modified progression-free survival on the vertical axis. The plot includes patient numbers at risk over time and markers indicating censored data points.*

FDA Label Image

Figure 2 (Figure2)

Kaplan-Meier curve showing IRF-assessed progression-free survival over time (months) comparing Brentuximab Vedotin plus Best Supportive Care (BV+BSC) against Placebo plus Best Supportive Care (Placebo+BSC) in Study 3: AETHERA. The graph plots percentage of subjects free of progression or death from 0 to 52 months, with median survival times and statistical data included.*

FDA Label Image

Figure 3 (Figure3)

Kaplan-Meier curve depicting IRF-assessed progression-free survival in Study 6: ECHELON-2, comparing A+CHP versus CHOP treatment groups over time from randomization in months. The graph includes hazard ratio, median survival times, and number of patients at risk and events for each group.*

FDA Label Image

Figure4

A line chart titled 'Overall Survival (Study 6: ECHELON-2)' comparing the percentage of surviving patients over time in months after randomization between two treatment groups: A+CHP (blue line) and CHOP (black line). The y-axis represents the percentage of surviving patients, and the x-axis represents time from randomization in months, up to 66 months. The chart includes a table with median months, hazard ratio, 95% confidence interval, and log-rank p-value, showing survival analysis details for each group and the number of patients at risk over time below the graph.*

FDA Label Image

Figure5

Kaplan-Meier curve showing progression-free survival over time (months from randomization) for two treatment groups: Brentuximab Vedotin and Methotrexate or Bexarotene. The plot illustrates the probability of progression-free survival, with patient numbers at risk listed below the time axis for each group.*

FDA Label Image

Seattle Genetics (Logo)

The packaging label for ADCETRIS 50 mg/10.5 mL injection, a lyophilized powder for solution administered intravenously. The label includes the brand name ADCETRIS prominently and the active ingredient brentuximab vedotin. The labeler is SEAGEN INC., and the product NDC is 51144-050. The background is primarily white with green and black text and the Seagen logo at the top left.*

FDA Label Image

Structural Formula (Structuralformula)

Chemical structure diagram of brentuximab vedotin, the active ingredient in ADCETRIS injection, powder, lyophilized, for solution. The structure shows the molecular arrangement of the compound as depicted in the submitted image.*

FDA Label Image

Trademark Logo (Tm Logo)

ADCETRIS 50 mg injection vial containing brentuximab vedotin as a lyophilized powder for intravenous solution, manufactured by SEAGEN INC. The vial has a beige cap and clear label with black text.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.